Expertise in
2
conditions

Ella Evron

Jerusalem, JM, IL 
Expertise in
2
conditions
Jerusalem, JM, IL 

Overview

Ella Evron practices practicing medicine in Jerusalem, Israel.

Ms. Evron is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, BRCA Positive Breast Cancer, and Mastectomy.

She is actively involved in clinical research, co-authoring 36 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Jerusalem, JM, Israel
Other Locations
Tel Aviv, TA, Israel
Rehovot, M, Israel
Rishon Leziyyon, M 70300, Israel
Zerifin, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
View 1 Less Clinical Trial

36 Total Publications

Correction: Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer.
Correction: Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer.
Journal: Oncogene
Published: September 05, 2025

Frequently Asked Questions about Ella Evron

Is Ella Evron a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Ella Evron is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ella Evron participate in research or clinical trials?

Yes. Ella Evron has published 36 articles and abstracts on conditions like Breast Cancer. You can view a list of Ella Evron's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Evron's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile